Ranbaxy Labs awaits FDA re-inspection

Ranbaxy Laboratories said FDA may start inspection of its Dewas, India, plant "any time now," moving the Indian company closer to resuming exports to the world's largest pharmaceutical market from the facility. Report

Suggested Articles

Pfizer has scored FDA approval for its Humira biosimilar, but it can't launch the product for several years under a patent settlement.

The 3-2 vote on the deal was split along the party lines, spelling trouble for future biopharma M&A deals should Democrats move into the White House.

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.